Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab in relapsed or refractory classical Hodgkin Lymphoma
NCT03505996Phase 2Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- May 2018
- Primary completion
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sugemalimab in Classical Hodgkin Lymphoma (cHL), sponsored by CStone Pharmaceuticals. Primary endpoint: Objective Response Rate. Started May 2018; status: completed.
02
Drugs
sugemalimab
03
Conditions
Classical Hodgkin Lymphoma (cHL)
Beyond the preview
Go deeper on NCT03505996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505996.